anti-Zika Virus Envelope Protein (EIII domain), mAb (rec.) (neutralizing) (ZKA64) (preservative free)

anti-Zika Virus Envelope Protein (EIII domain), mAb (rec.) (neutralizing) (ZKA64) (preservative free)

Antibodies Primary

Article No

AG-27B-6004PF-C100

Species Reactivity

virus

Size

100 ug

Clone

ZKA64

Source / Host

human

Shipping Information

BLUE ICE

Application

Block, FA

Article No

AG-27B-6004PF-C100

Species Reactivity

virus

Size

100 ug

Clone

ZKA64

Source / Host

human

Shipping Information

BLUE ICE

Application

Block, FA

Specifications

Additional Information Source: EBV-immortalized memory B cells derived from ZIKV-infected, DENV-naïve human donors.
Application Block, FA
Article No AG-27B-6004PF-C100
Country Availability SE, FI, DK, NO, IS, EE, LV, LT
Clone ZKA64
Clone Type monoclonal
Concentration 1 mg/ml
Conjugation Unconjugated
Description anti-Zika Virus Envelope Protein (EIII domain), mAb (rec.) (neutralizing) (ZKA64) (preservative free)
Supplier Adipogen Life Sciences
Endotoxin <0.001EU/µg
Additional Information Source: EBV-immortalized memory B cells derived from ZIKV-infected, DENV-naive human donors.
Format Liquid
Immunogen Zika Virus
Isotype IgG1 k
Notes Recombinant Antibody. Recognizes and binds specifically to the EDIII domain of the Zika Virus envelope protein (ZIKV E). It does not cross-react with Dengue virus envelope protein (DENV E). Species cross-reactivity: Virus. Clone: ZKA64. Isotype: Human IgG1kappa. Applications: FUNC, FUNC (Blocking). Host: . Liquid. In PBS. The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barre syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry; EDII containing the fusion loop; and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV.|The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barre syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry; EDII containing the fusion loop; and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV.
Alias Names ZIKV E Protein
Product Type Antibodies Primary
Protocol Source: EBV-immortalized memory B cells derived from ZIKV-infected, DENV-naïve human donors.
Purity >95%
Research area Inflammation
Shipping Information BLUE ICE
Size 100 ug
Source / Host human
Species Reactivity virus
Stability Stable for at least 1 year after receipt when stored at -20°C. Stable for at least 3 months after receipt when stored at +4°C.
Storage -20°C, 4°C
Substrate / Buffer Liquid. In PBS.
Technical Specifications Recombinant Antibody. Recognizes and binds specifically to the EDIII domain of the Zika Virus envelope protein (ZIKV E). It does not cross-react with Dengue virus envelope protein (DENV E). Species cross-reactivity: Virus. Clone: ZKA64. Isotype: Human IgG1kappa. Applications: FUNC, FUNC (Blocking). Host: . Liquid. In PBS. The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barré syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry; EDII containing the fusion loop; and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV.
Product Page Updated 2024-02-01T08:25:01.492Z

Documentation

References

Show more
Shipping info
The delivery time for this item is approximately 5-8 business days. Read more